SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Elevance Health Investors

NEW YORK, July 3, 2025 – Faruqi & Faruqi, LLP, a prominent national securities law firm, has announced an ongoing investigation into potential claims against Elevance Health, Inc. ("Elevance" or the "Company") (NYSE: ELV). This investigation comes as the firm encourages investors who may have suffered financial losses related to their Elevance securities to come forward and explore their legal options.

Securities Litigation Partner James (Josh) Wilson of Faruqi & Faruqi, LLP, is actively reaching out to investors who purchased or acquired Elevance securities between April 18, 2024, and October 16, 2024. These investors are encouraged to contact Mr. Wilson directly to discuss their potential legal rights and avenues for recourse. The firm emphasizes the importance of understanding one's options, especially for those who experienced adverse financial impacts during this specified period.

The Federal Securities Class Action and Lead Plaintiff Deadline

Investors are reminded of a critical deadline: July 11, 2025. This date marks the deadline for investors to seek the role of lead plaintiff in a federal securities class action lawsuit that has already been filed against Elevance Health. Becoming a lead plaintiff allows an investor to take a more active role in the litigation, overseeing the attorneys and making key decisions on behalf of the class of investors. This is a significant opportunity for affected shareholders to influence the direction and potential outcome of the lawsuit.

Faruqi & Faruqi, LLP, known for its extensive experience in securities litigation, is committed to representing investors who have been harmed by alleged corporate misconduct. The firm's investigation into Elevance Health underscores its dedication to holding companies accountable and seeking compensation for shareholders.

Understanding the Implications for Investors

For investors holding Elevance Health (ELV) stock, this announcement carries significant implications. While the specific allegations underlying the class action are not detailed in this notice, the initiation of such an investigation typically suggests concerns regarding potential misrepresentations, omissions, or other violations of federal securities laws that may have artificially inflated the company's stock price during the specified period. If proven, such actions could have led to investor losses when the true information became public.

Investors who purchased ELV shares between April 18, 2024, and October 16, 2024, should carefully review their investment records. Even if the losses seem minor, participating in a class action lawsuit can be beneficial as it pools resources and strengthens the collective bargaining power of affected shareholders. It's crucial to consult with legal counsel to understand how this investigation and the ongoing class action might affect individual portfolios.

Market Context and Investment Insights

Elevance Health, a major player in the healthcare industry, operates in a highly regulated and dynamic environment. News of a securities investigation can introduce uncertainty and volatility into a company's stock performance. While the immediate impact on ELV's stock price may vary, such legal challenges often lead to increased scrutiny from analysts and investors alike. The healthcare sector, in general, is subject to various regulatory pressures, and legal proceedings can sometimes signal underlying operational or compliance issues.

Actionable Insights for Investors:

• Review Holdings: Immediately check if you purchased Elevance Health (ELV) securities between April 18, 2024, and October 16, 2024.
• Contact Legal Counsel: Reach out to Faruqi & Faruqi, LLP, or another qualified securities litigation firm, to discuss your specific situation and understand your rights. You can contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
• Consider Lead Plaintiff Role: If you suffered significant losses, consider applying to be a lead plaintiff before the July 11, 2025, deadline. This role offers greater control over the litigation process.
• Stay Informed: Monitor official company announcements, SEC filings, and financial news regarding Elevance Health and the ongoing legal proceedings.

This investigation serves as a reminder of the inherent risks in equity investments and the importance of due diligence. While the outcome of the class action is uncertain, proactive engagement by affected investors is key to protecting their interests.

For additional information, investors may also click here to visit Faruqi & Faruqi's website.